Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituxan in Children With Duchenne Muscular Dystrophy (DMD)
NCT07475754Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2026
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
01
Overview
Open-label, single-arm trial of rituximab in Duchenne muscular dystrophy (DMD), sponsored by Peking Union Medical College Hospital. Primary endpoint: Incidence of adverse events at 1 year. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT07475754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07475754.